Dana Carroll, PhD

Research Interests

  • Genome Engineering
  • DNA Repair
  • CRISPRs
  • TALENs
  • Zinc-Finger Nucleases

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Biochemistry - Distinguished Professor
  • Cancer Center Programs: Nuclear Control of Cell Growth & Differentiation

Academic Office Information

  • 801-581-5977
  • Emma Eccles Jones Research Building
    Biochemistry
    15 North Medical Drive East, Room: 4520B
    Salt Lake City, UT 84112

Academic Bio

Dana Carroll, PhD, is a Distinguished Professor in the Department of Biochemistry at the University of Utah School of Medicine and a member of the Nuclear Control of Cell Growth and Differentiation Program at the Huntsman Cancer Institute.

Carroll’s research involves genome engineering using targetable nucleases. His lab pioneered the development of zinc-finger nucleases as gene targeting tools and continued working with the more recent TALENs and CRISPR/Cas nucleases. Much of the effort was focused on optimizing the efficiency of these reagents for targeted mutagenesis and gene replacement, which could ultimately provide treatment for many diseases, including certain types of cancer. This technology has now been applied to more than 200 different organisms, including current clinical trials in humans and improvements in crop plants and livestock. Carroll's current interests include societal implications of genome editing.

Carroll received his bachelor’s degree from Swarthmore College, Pennsylvania, and his PhD from the University of California, Berkeley. He did postdoctoral research at the Beatson Institute for Cancer Research in Glasgow, Scotland, and at the Carnegie Institution Department of Embryology in Baltimore.

Education History

Type School Degree
Postdoctoral Fellowship Carnegie Institution of Washington
Department of Embryology, advisor: Donald D. Brown
Postdoctoral Fellow
Postdoctoral Fellowship Beatson Institute for Cancer Research
advisor: John Paul
Postdoctoral Fellow
Doctoral Training University of California, Berkeley
Department of Chemistry, thesis advisor: Ignacio Tinoco, Jr.
Ph.D.
Undergraduate Swarthmore College
Chemistry
B.A.

Global Impact

Education History

Type School Degree Country
Postdoctoral Fellowship Beatson Institute for Cancer Research
advisor: John Paul
Postdoctoral Fellow United Kingdom

Career

Institution Description Country
Institut Curie Visiting Professor France
Edinburgh University, MRC Mammalian Genome Unit Visiting Scholar United Kingdom

Selected Publications

Journal Article

  1. Carroll D (2018). p53 Throws CRISPR a Curve. Trends Pharmacol Sci, 39(9), 783-784.
  2. Urnov FD, Ronald PC, Carroll D (2018). A call for science-based review of the European court's decision on gene-edited crops. Nat Biotechnol, 36(9), 800-802.
  3. Yarrington RM, Verma S, Schwartz S, Trautman JK, Carroll D (2018). Nucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo.LID - 201810062 [pii]LID - 10.1073/pnas.1810062115 [doi]. (Epub ahead of print) Proc Natl Acad Sci U S A.
  4. DeWitt MA, Corn JE, Carroll D (2017 May 15). Genome editing via delivery of Cas9 ribonucleoprotein. Methods, 121-122, 9-15.
  5. Chandrasegaran S, Bullen CK, Carroll D (2017 Oct 2). Genome editing of human embryos: to edit or not to edit, that is the question. J Clin Invest, 127(10), 3588-3590.
  6. Sarno R, Vicq Y, Uematsu N, Luka M, Lapierre C, Carroll D, Bastianelli G, Serero A, Nicolas A (2017 Nov 2). Programming sites of meiotic crossovers using Spo11 fusion proteins. Nucleic Acids Res, 45(19), e164.
  7. Carroll D, Van Eenennaam AL, Taylor JF, Seger J, Voytas DF (2016). Regulate genome-edited products, not genome editing itself. Nat Biotechnol, 34(5), 477-9.
  8. DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, Heo SJ, Mitros T, Munoz DP, Boffelli D, Kohn DB, Walters MC, Carroll D, Martin DI, Corn JE (2016). Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 8(360), 360ra134.
  9. Carroll D (2016 Nov 15). Genome editing: progress and challenges for medical applications. Genome Med, 8(1), 120.
  10. Carroll D (2016). A Perspective on the State of Genome Editing. Mol Ther, 24(3), 412-3.
  11. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg SH, Weissman JS, Yamamoto KR (2015). Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science, 348(6230), 36-8.
  12. Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng G, Greely HT, Isasi R, Ji W, Kim JS, Knoppers B, Lanphier E, Li J, Lovell-Badge R, Martin GS, Moreno J, Naldini L, Pera M, Perry AC, Venter JC, Zhang F, Zhou Q (2015). CRISPR germline engineering--the community speaks. Nat Biotechnol, 33(5), 478-86.
  13. Carroll D, Charo RA (2015). The societal opportunities and challenges of genome editing. Genome Biol, 16(1), 242.
  14. Carroll D (2014). Precision genome engineering. Curr Biol, 24(3), R102-3.
  15. Carroll D, Beumer KJ (2014). Genome engineering with TALENs and ZFNs: repair pathways and donor design. Methods, 69(2), 137-41.
  16. Cho SW, Lee J, Carroll D, Kim JS, Lee J (2013). Heritable gene knockout in Caenorhabditis elegans by direct injection of Cas9-sgRNA ribonucleoproteins. Genetics, 195(3), 1177-80.
  17. Beumer KJ, Trautman JK, Christian M, Dahlem TJ, Lake CM, Hawley RS, Grunwald DJ, Voytas DF, Carroll D (2013). Comparing zinc finger nucleases and transcription activator-like effector nucleases for gene targeting in Drosophila. G3 (Bethesda), 3(10), 1717-25.
  18. Carroll D (2013). Staying on target with CRISPR-Cas. Nat Biotechnol, 31(9), 807-9.
  19. Beumer KJ, Trautman JK, Mukherjee K, Carroll D (2013). Donor DNA Utilization during Gene Targeting with Zinc-finger Nucleases.LID - g3.112.005439v2 [pii]LID - 10.1534/g3.112.005439 [doi]. (Epub ahead of print) G3 (Bethesda).

Review

  1. Carroll D (2017). Genome Editing: Past, Present, and Future. [Review]. Yale J Biol Med, 90(4), 653-659.
  2. Carroll D (2015). Genome editing by targeted chromosomal mutagenesis. [Review]. Methods Mol Biol, 1239, 1-13.
  3. Chandrasegaran S, Carroll D (2015). Origins of Programmable Nucleases for Genome Engineering.LID - S0022-2836(15)00606-3 [pii]LID - 10.1016/j.jmb.2015.10.014 [doi]. [Review]. J Mol Biol.
  4. Pauwels K, Podevin N, Breyer D, Carroll D, Herman P (2014). Engineering nucleases for gene targeting: safety and regulatory considerations. [Review]. New Biotechnology, 31(1), 18-27.
  5. Beumer KJ, Carroll D (2014). Targeted genome engineering techniques in Drosophila. [Review]. Methods, 68(1), 29-37.
  6. Carroll D (2014). Genome engineering with targetable nucleases. [Review]. Annu Rev Biochem, 83, 409-39.
  7. Carroll D (2012). A CRISPR approach to gene targeting. [Review]. Mol Ther, 20(9), 1658-60.

Patent

  1. Carroll D, Bibikova M, Golic KG, Golic M, Drews GN (January 31, 2012). Target Chromosomal Mutagenesis Using Zinc Finger Nucleases. U.S. Patent No. 8106255. Washington, D.C.:U.S. Patent and Trademark Office.